VAPES 101
- Jon M.
- Nov 30
- 2 min read
UNDERSTANDING THE ROLE OF VAPOURIZED CANNABIS IN MEDICAL PRACTICE
WHY PRESCRIBE VAPOURIZED CANNABIS
Vapourized cannabis represents a precise, fast-acting, and controlled method of cannabinoid delivery that can support a range of patient needs. For clinicians, the format bridges the gap between the immediate onset of inhalation and the predictable consistency of modern formulation technology.
Compared with traditional flower, vapourized products offer:
Rapid onset (1–5 minutes), providing near-immediate symptom relief.
Controlled dosing, with consistent output per puff.
Reduced exposure to combustion by-products, in line with a harm-reduction approach.
When compared with oral oils or capsules, which often require 30 to 90 minutes for onset, vapourization enables titration in real time. This can be particularly valuable for patients managing breakthrough pain, acute anxiety, or nausea, where timing and dose flexibility are critical.
Vapourization also offers discretion, reproducibility, and patient adherence advantages, aligning with the principles of precision medicine and clinician-supervised therapy.
UNDERSTANDING THE TECHNOLOGY AND QUALITY CONTROLS
At Organigram, each vapourized product is engineered to meet rigorous performance and safety standards comparable to those applied in other inhalation-based therapies. Our Edison and BOXHOT vapes use CCELL and Jupiter hardware—trusted, globally recognized manufacturers known for consistent aerosol generation, precise temperature control, and proven reliability under varied use conditions.
Every device and formulation undergoes extensive validation through our internal Product Development Centre (PDC). Testing confirms uniform puff profiles, total aerosol mass per puff, and device longevity across both light and heavy user simulations. Leakage and end-of-cart life evaluations verify that each cartridge maintains stable performance and accurate cannabinoid delivery until its final puff.
All products are subject to comprehensive release testing, including heavy-metal, microbial, and stability assessments. Lifetime toxicology risk evaluations, conducted by Organigram’s Innovation Team, confirm the absence of harmful degradation products under expected use.
Additional studies covering extractables and leachables, stability, and alignment between Canadian and Australian release standards ensure compliance with EU-GMP and Therapeutic Goods Administration (TGA) requirements.
These processes reinforce that Organigram’s vapourized products are not only effective but scientifically validated and manufactured with patient safety at their core, providing prescribers with confidence in both device integrity and formulation quality.
